Slaying the pre-TCR beast Summary "Slaying the pre-TCR beast" likely refers to overcoming challenges and inefficiencies in traditional Request for Change (RFC) processes before implementing a more streamlined and automated Technical Change Request (Read More
Tags :Cancer Research
The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma Summary CAR-T cell therapy for multiple myeloma significantly alters the patient’s existing T cell population. This Read More
Education, Research & Positions
Enhanced patient selection with quantitative continuous scoring of PD-L1 expression
Enhanced patient selection with quantitative continuous scoring of PD-L1 expression for IO treatment in metastatic NSCLC Summary Quantitative, continuous scoring of PD-L1 expression offers improved patient selection for immunotherapy (IO) treatment in metastatic non-small cell Read More
Education, Research & Positions
EchoBack-CAR T cells: a sonogenetic solution to the persistent challenges
EchoBack-CAR T cells: a sonogenetic solution to the persistent challenges of solid tumor immunotherapy Summary EchoBack-CAR T cells offer a novel approach to solid tumor immunotherapy by addressing key limitations of traditional CAR T-cell therapies. Read More
Education, Research & Positions
Downregulation of MICA/MICB improves cell persistence and clinical activity of
Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia Summary CAR T-cell therapy targeting NKG2D ligands (Read More
Education, Research & Positions
Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary
Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma Summary Plasmapheresis, a procedure that filters blood, has shown promise in overcoming resistance to anti-BCMA immunotherapies for multiple Read More
Education, Research & Positions
Publisher Correction: GD2-targeting CAR T cells in high-risk neuroblastoma: a
Publisher Correction: GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial Summary A phase 1/2 clinical trial investigated the safety and efficacy of GD2-targeting CAR T cells in children and young adults with Read More
CD160+CD8+ T cells for improved immunotherapy Summary CD160+CD8+ T cells are a subset of cytotoxic T lymphocytes (CTLs) with enhanced antitumor activity. CD160, an activating receptor, distinguishes these cells and contributes to their Read More
Education, Research & Positions
CD160 dictates anti-PD-1 immunotherapy resistance by regulating CD8+ T cell
CD160 dictates anti-PD-1 immunotherapy resistance by regulating CD8+ T cell exhaustion in colorectal cancer Summary CD160, a surface receptor on CD8+ T cells, plays a crucial role in resistance to anti-PD-1 immunotherapy in colorectal cancer (Read More
Education, Research & Positions
Efficacy and safety of induction immunotherapy plus chemotherapy in patients
Efficacy and safety of induction immunotherapy plus chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a meta-analysis Summary This meta-analysis investigates the efficacy and safety of adding induction immunotherapy to chemotherapy for locoregionally advanced nasopharyngeal Read More
Site Logo
Powered by AI
New Journal Citation Reports (JCR) 2025
All-Time Views
1 Million+ Views and Counting..!
Follow me on Linkedin for Latest Jobs and Scholarships
Subscribe Youtube
Celebrating 7 Years
It has been 7 years since it was launched in late July 2018, and it is moving forward. Appreciate all the respected visitors! Please share this site with your friends to push science forward and improve human health.
Site Trust Score
Google Safe
